These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1205 related articles for article (PubMed ID: 10053096)

  • 21. Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group).
    Wimberger P; Wehling M; Lehmann N; Kimmig R; Schmalfeldt B; Burges A; Harter P; Pfisterer J; du Bois A
    Ann Surg Oncol; 2010 Jun; 17(6):1642-8. PubMed ID: 20165986
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of surgical cytoreduction in Stage IV endometrial carcinoma.
    Chi DS; Welshinger M; Venkatraman ES; Barakat RR
    Gynecol Oncol; 1997 Oct; 67(1):56-60. PubMed ID: 9345357
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer.
    Aletti GD; Dowdy SC; Gostout BS; Jones MB; Stanhope CR; Wilson TO; Podratz KC; Cliby WA
    Obstet Gynecol; 2006 Jan; 107(1):77-85. PubMed ID: 16394043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns.
    Park JY; Seo SS; Kang S; Lee KB; Lim SY; Choi HS; Park SY
    Gynecol Oncol; 2006 Dec; 103(3):977-84. PubMed ID: 16837030
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients.
    Colombo PE; Mourregot A; Fabbro M; Gutowski M; Saint-Aubert B; Quenet F; Gourgou S; Rouanet P
    Eur J Surg Oncol; 2009 Feb; 35(2):135-43. PubMed ID: 18289825
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?
    Chi DS; Eisenhauer EL; Lang J; Huh J; Haddad L; Abu-Rustum NR; Sonoda Y; Levine DA; Hensley M; Barakat RR
    Gynecol Oncol; 2006 Nov; 103(2):559-64. PubMed ID: 16714056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer.
    Gadducci A; Iacconi P; Cosio S; Fanucchi A; Cristofani R; Riccardo Genazzani A
    Gynecol Oncol; 2000 Dec; 79(3):344-9. PubMed ID: 11104603
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
    Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer.
    Aletti GD; Dowdy SC; Podratz KC; Cliby WA
    Gynecol Oncol; 2006 Feb; 100(2):283-7. PubMed ID: 16182350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Factors affecting disease recurrence and the role of secondary therapies in the management for patients with recurrent ovarian carcinoma].
    Zang R; Zhang Z; Cai S
    Zhonghua Fu Chan Ke Za Zhi; 2002 Sep; 37(9):546-9. PubMed ID: 12411017
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic factors responsible for survival in sex cord stromal tumors of the ovary--a multivariate analysis.
    Chan JK; Zhang M; Kaleb V; Loizzi V; Benjamin J; Vasilev S; Osann K; Disaia PJ
    Gynecol Oncol; 2005 Jan; 96(1):204-9. PubMed ID: 15589602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Impacts of chemotherapy on long-term survival of patients with advanced epithelial ovarian cancer].
    Zang R; Cai S; Zhang Z
    Zhonghua Fu Chan Ke Za Zhi; 2001 Dec; 36(12):738-41. PubMed ID: 16136895
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome.
    Salani R; Santillan A; Zahurak ML; Giuntoli RL; Gardner GJ; Armstrong DK; Bristow RE
    Cancer; 2007 Feb; 109(4):685-91. PubMed ID: 17219441
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Paclitaxel-based chemotherapy in carcinoma of the fallopian tube.
    Gemignani ML; Hensley ML; Cohen R; Venkatraman E; Saigo PE; Barakat RR
    Gynecol Oncol; 2001 Jan; 80(1):16-20. PubMed ID: 11136563
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of secondary cytoreductive surgery for recurrent mucinous epithelial ovarian cancer (mEOC).
    Cheng X; Jiang R; Li ZT; Tang J; Cai SM; Zhang ZY; Tian WJ; Zang RY
    Eur J Surg Oncol; 2009 Oct; 35(10):1105-8. PubMed ID: 19443175
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of cytoreduction in stage III and IV uterine papillary serous carcinoma.
    Thomas MB; Mariani A; Cliby WA; Keeney GL; Podratz KC; Dowdy SC
    Gynecol Oncol; 2007 Nov; 107(2):190-3. PubMed ID: 17825394
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma.
    Tebes SJ; Sayer RA; Palmer JM; Tebes CC; Martino MA; Hoffman MS
    Gynecol Oncol; 2007 Sep; 106(3):482-7. PubMed ID: 17590420
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic factors and role of salvage surgery in chemorefractory ovarian germ cell malignancies: a study in Chinese patients.
    Li J; Yang W; Wu X
    Gynecol Oncol; 2007 Jun; 105(3):769-75. PubMed ID: 17459461
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study.
    Ansquer Y; Leblanc E; Clough K; Morice P; Dauplat J; Mathevet P; Lhommé C; Scherer C; Tigaud JD; Benchaib M; Fourme E; Castaigne D; Querleu D; Dargent D
    Cancer; 2001 Jun; 91(12):2329-34. PubMed ID: 11413522
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survival probability in ovarian clear cell adenocarcinoma.
    Kennedy AW; Markman M; Biscotti CV; Emery JD; Rybicki LA
    Gynecol Oncol; 1999 Jul; 74(1):108-14. PubMed ID: 10385560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 61.